https://www.selleckchem.com/products/SB-203580.html Diagnosing cutaneous cytomegalovirus (CMV) is difficult due to its rarity and diverse manifestations, and early recognition is crucial as it may indicate disseminated disease and a poor prognosis. We examined a 71-year-old Taiwanese male presenting with a 1-week history of progressive, painful papulopustules associated with superficial ulcers and thick yellowish crusts on the scalp. He had been diagnosed with stage IVb lung adenocarcinoma 6 weeks earlier, and the epidermal growth factor receptor inhibitor (EGFRI) erlotinib and radiotherapy had been started to treat brain metastases 1 month before he came to our clinic. Histopathological examination of a scalp lesion and ELISA and PCR testing of blood samples were indicative of disseminated CMV infection. Unfortunately, the patient passed away the day after his scalp biopsy, before the investigations confirmed the infection. We would like to highlight the importance of remaining vigilant for cutaneous CMV in end-stage cancer patients receiving tyrosine kinase inhibitors (TKIs) and recognizing how this potentially life-threatening viral infection can masquerade as a possible side effect of erlotinib.The use of retaining glycoside hydrolases as synthetic tools for glycochemistry is highly topical and the focus of considerable research. However, due to the incomplete identification of the molecular determinants of the transglycosylation/hydrolysis partition (t/h), rational engineering of retaining glycoside hydrolases to create transglycosylases remains challenging. Therefore, to understand better the factors that underpin transglycosylation in a GH51 retaining α-l-arabinofuranosidase from Thermobacillus xylanilyticus, the investigation of this enzyme's active site was pursued. Specifically, the properties of two mutants, F26L and L352M, located in the vicinity of the active site are described, using kinetic and 3D structural analyses and molecular dynamics simulations